Overview

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

Status:
Not yet recruiting
Trial end date:
2025-03-03
Target enrollment:
Participant gender:
Summary
This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S